Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Alnylam Pharmaceuticals Shares Rise After Goldman Sachs Upgrade

11/22/2021 | 12:27pm EST


ę MT Newswires 2021
All news about ALNYLAM PHARMACEUTICALS, INC.
11:59aSVB Leerink Adjusts Alnylam Pharmaceuticals' Price Target to $109 from $108, Keeps Mark..
MT
01/24Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigation..
AQ
01/24Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financi..
BU
01/21Health Care Stocks Decline Pre-Bell Friday
MT
01/21Alnylam Pharmaceuticals Says Vutrisiran Met All Secondary Endpoints from HELIOS-A Phase..
MT
01/21Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigation..
BU
01/21Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigation..
CI
01/20HC Wainwright Boosts Price Target on Alnylam Pharmaceuticals to $350 From $250, Keeps B..
MT
01/18Morgan Stanley Adjusts Alnylam Pharmaceuticals' Price Target to $215 from $226, Keeps O..
MT
01/17Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
AQ
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 822 M - -
Net income 2021 -759 M - -
Net cash 2021 1 321 M - -
P/E ratio 2021 -19,8x
Yield 2021 -
Capitalization 15 211 M 15 211 M -
EV / Sales 2021 16,9x
EV / Sales 2022 11,3x
Nbr of Employees 1 453
Free-Float 99,4%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 127,18 $
Average target price 211,24 $
Spread / Average Target 66,1%
EPS Revisions
Managers and Directors
Yvonne L. Greenstreet President, Chief Operating Officer & Director
Akshay K. Vaishnaw President
Jeffrey V. Poulton Executive VP, Chief Financial & Accounting Officer
Michael W. Bonney Independent Director
Pushkal Garg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.-25.00%15 211
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892